Phibro Animal Health (NASDAQ:PAHC) Issues FY 2026 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.980-3.100 for the period, compared to the consensus EPS estimate of 3.030. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Phibro Animal Health Price Performance

PAHC stock traded up $2.26 on Wednesday, reaching $58.50. 300,750 shares of the company’s stock were exchanged, compared to its average volume of 273,204. Phibro Animal Health has a twelve month low of $19.00 and a twelve month high of $60.08. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The stock has a fifty day moving average of $53.93 and a 200-day moving average of $46.34. The firm has a market cap of $2.37 billion, a PE ratio of 26.00, a P/E/G ratio of 0.84 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities analysts predict that Phibro Animal Health will post 3.03 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be given a $0.12 dividend. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 21.33%.

Analysts Set New Price Targets

PAHC has been the topic of several recent research reports. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Finally, Citigroup started coverage on Phibro Animal Health in a report on Wednesday, April 15th. They issued a “neutral” rating and a $62.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.40.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 110,842 shares of Phibro Animal Health stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96. Following the transaction, the chief executive officer owned 122,958 shares in the company, valued at approximately $5,948,708.04. This trade represents a 47.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 281,600 shares of company stock valued at $14,334,853. Company insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd grew its position in Phibro Animal Health by 125.4% in the fourth quarter. XTX Topco Ltd now owns 16,233 shares of the company’s stock valued at $606,000 after acquiring an additional 9,032 shares in the last quarter. Nebula Research & Development LLC increased its position in shares of Phibro Animal Health by 13.6% during the second quarter. Nebula Research & Development LLC now owns 22,833 shares of the company’s stock worth $583,000 after acquiring an additional 2,739 shares during the last quarter. Deutsche Bank AG grew its stake in Phibro Animal Health by 18.8% during the 4th quarter. Deutsche Bank AG now owns 14,767 shares of the company’s stock valued at $552,000 after purchasing an additional 2,341 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at approximately $329,000. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of Phibro Animal Health by 32.3% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 8,650 shares of the company’s stock worth $323,000 after buying an additional 2,110 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.